Singapore markets close in 6 hours 33 minutes
Straits Times Index
3,153.91 +15.01 (+0.48%) Nikkei
27,054.67 +62.46 (+0.23%) Hang Seng
17,828.89 +749.38 (+4.39%) FTSE 100
7,086.46 +177.70 (+2.57%) BTC-USD
20,209.83 +683.32 (+3.50%) CMC Crypto 200
458.35 +12.91 (+2.90%)
SpringWorks Therapeutics, Inc. (SWTX)
NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 27.03 |
| Open | 27.42 |
| Bid | 26.71 x 2200 |
| Ask | 29.69 x 1100 |
| Day's range | 26.78 - 28.39 |
| 52-week range | 13.60 - 77.70 |
| Volume | |
| Avg. volume | 909,548 |
| Market cap | 1.761B |
| Beta (5Y monthly) | 0.84 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -4.23 |
| Earnings date | 02 Nov 2022 - 07 Nov 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 79.60 |
- Zacks
SpringWorks (SWTX) Down Despite Desmoid Tumors Study Meeting Goal
SpringWorks' (SWTX) phase III study evaluating its investigational candidate, nirogacestat, in adult patients with progressing desmoid tumors, meets primary and key secondary endpoints.
- Zacks
Allogene (ALLO) Focuses on Pipeline Amid Lack of Marketed Drugs
With no product revenues due to the lack of marketed drugs, Allogene (ALLO) focuses on developing its pipeline candidates that mainly consist of allogenic CAR T therapies.
- Zacks
SpringWorks (SWTX) & AbbVie Unite for Multiple Myeloma Drug
SpringWorks Therapeutics (SWTX) collaborates with AbbVie (ABBV) to evaluate the combination of nirogacestat with AbbVie's ABBV-383 for relapsed or refractory multiple myeloma.
© 2022 Yahoo. All rights reserved.
